Emma Walmsley, GSK CEO (GSK Investor Day 5)
July 15, 2022 10:29 AM EDTUpdated July 18, 06:56 AM
Bioregnum
Pharma

As the con­sumer group splits away to­day, what will New GSK buy now?

What a dif­fer­ence one re­al­ly good Phase III read­out and a cou­ple of late-stage buy­outs can make.

GSK CEO Em­ma Walm­s­ley has been try­ing, hard …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Bio­Marin turns to ex-Roche deal­mak­er James Sabry to build ‘next ver­sion’ of 27-year-old com­pa­ny

Pur­due, Sack­lers reach new $7.4B opi­oid set­tle­ment af­ter SCO­TUS re­jec­tion

As an­oth­er Trump term gets un­der­way, phar­ma ad­vi­sors get com­fort­able with un­cer­tain­ty

Chi­na's biotech boom is threat­en­ing US drug­mak­er­s' dom­i­nance

Ab­b­Vie part­ners with Neo­morph in lat­est mol­e­c­u­lar glue deal

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times